Industry News
Insights into the mechanisms underlying angiogenesis in lung metastases
Aug 19, 2013
Cancer metastasis requires tumor cells to acquire properties that allow them to escape from the primary tumor site, travel to a distant place in the body, and form secondary tumors. But first, an advance team of molecules produced by the primary tumor sets off a series of events that create a network of nurturing blood vessels for arriving primary tumor cells to set up shop... Read More
Attacking the architecture of the cancer cell may help children with hard-to-treat neuroblastoma
Aug 19, 2013
Children with a particularly lethal cancer could benefit from potentially life-saving treatment, following breakthrough work led by researchers at the University of New South Wales (UNSW). A whole new class of drugs has been developed that, for the first time, targets the structure of the cancer cell... Read More
Fighting cancer with nanoparticles
Aug 17, 2013
Researchers at the University of Georgia are developing a new treatment technique that uses nanoparticles to reprogram immune cells so they are able to recognize and attack cancer. The findings were published recently in the early online edition of ACS Nano. The human body operates under a constant state of martial law... Read More
Study of melittin-based pore formation has implications for fighting cancer and bacteria
Aug 17, 2013
A new study by Rice University biophysicists offers the most comprehensive picture yet of the molecular-level action of melittin, the principal toxin in bee venom. The research could aid in the development of new drugs that use a similar mechanism as melittin's to attack cancer and bacteria. The study appears in the Proceedings of the National Academy of Sciences... Read More
Research 'backs watchful waiting' in prostate cancer
Aug 16, 2013
Prostate cancer researchers publishing in the Cancer Research journal argue for more watchful waiting to manage the disease, rather than moving straight to aggressive treatment or surgery. "Radical prostatectomy or radiation therapy, the usual treatments for prostate cancer, can have negative side-effects such as impotence and incontinence," the lead researcher said... Read More
"Reprogrammed" treatment-resistant lymphomas respond to cancer drugs
Aug 16, 2013
A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research... Read More
NICE does not recommend Xalkori (Crizotinib) - a new advance in 'personalised medicine' for lung cancer patients
Aug 16, 2013
Pfizer Ltd has expressed concern and disappointment that the final appraisal determination (FAD) from the National Institute of Health and Care Excellence (NICE) does not recommend Xalkori (crizotinib) for previously treated, ALK positive advanced non small cell lung cancer (NSCLC)... Read More
Purdue innovation could improve personalized cancer-care outcomes
Aug 16, 2013
An innovation created by Purdue University researchers could improve therapy selection for personalized cancer care by helping specialists better identify the most effective drug treatment combinations for patients. David D. Nolte, a professor in Purdue's Department of Physics, and his collaborators Ran An, a graduate student in physics, and John J... Read More
NICE does not recommend Xalkoriq (crizotinib) - a new advance in 'personalised medicine' for lung cancer patients
Aug 16, 2013
Pfizer Ltd has expressed concern and disappointment that the final appraisal determination (FAD) from the National Institute of Health and Care Excellence (NICE) does not recommend Xalkori (crizotinib) for previously treated, ALK positive advanced non small cell lung cancer (NSCLC)... Read More
International team reveals 21 'signatures' in 30 common cancers
Aug 16, 2013
An international team, including scientists from Sydney's Garvan Institute of Medical Research and The University of Queensland, has described the mutational processes that drive tumour development in 30 of the most common cancer types. The discovery, published in Nature, one of the world's leading scientific journals, could help to treat and prevent a wide range of cancers... Read More
Previous Page Next Page